Researchers examined the cost and effectiveness of three antibiotics — metronidazole, vancomycin and fidaxomicin — and FMT to determine the cost-effectiveness of each one. They set a “willingness-to-pay” price threshold at $50,000 per quality-adjusted life-year.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Researchers found FMT’s cure rate was greater than 88.4 percent and its associated recurrence rate was less than 14.9 percent. FMT had an incremental cost-effectiveness ratio of $17,016 relative to oral vancomycin.
Researchers concluded FMT is the most cost-effective initial treatment for recurrent C. diff.
More Articles on Infection Control:
Many Hospital Infections Common Directly Outside Hospitals
Study: 43% of Internal Medicine Deaths are Infection-Related
Failing to Consider TB Potential Root Cause of TB Exposure
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
